Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entospletinib in Relapsed or Refractory Hematologic Malignancies
NCT01799889Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- Mar 2013
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of entospletinib in chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), lymphoplasmacytic lymphoma (LPL), sponsored by Gilead Sciences. Started Mar 2013; status: terminated.
02
Drugs
entospletinib
03
Conditions
chronic lymphocytic leukemia (CLL)mantle cell lymphoma (MCL)diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)lymphoplasmacytic lymphoma (LPL)
Beyond the preview
Go deeper on NCT01799889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01799889.